DOI: 10.1055/s-00000088

TumorDiagnostik & Therapie

References

Woyach JA, Ruppert AS, Heerema NA. et al.
Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202.

Blood 2018;
132: 6

Download Bibliographical Data

Search in: